Roche has gained approval from the European Commission (EC) for Tecentriq (atezolizumab) with chemotherapy (Abraxane) to treat patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).

The treatment targets adults whose tumours have a PD-L1 expression of more than 1% and have not previously received chemotherapy for the disease.

Roche chief medical officer and global product development head Sandra Horning said: “For the past 30 years, we have been dedicated to transforming the lives of people with breast cancer.

“Now, we are pleased to build on this foundation with the news that the first immunotherapy treatment for triple-negative breast cancer is available to people in Europe with PD-L1-positive, metastatic triple-negative breast cancer.”

“The European approval of this Tecentriq combination represents a significant step forward in the treatment of this aggressive breast cancer, where the unmet medical need is great.”

EC granted the approval based on results obtained from the Phase III IMpassion130 study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The progression-free survival (PFS) results indicated that Tecentriq plus nab-paclitaxel reduced the risk of progression by 38% when compared to nab-paclitaxel alone in people who tested positive for PD-L1 expression.

The combination of Tecentriq and nab-paclitaxel has shown a meaningful overall survival (OS) of seven months when compared to placebo and nab-paclitaxel for people with PD-L1-positive.

There are seven Phase III ongoing studies investigating the effect of Tecentriq in early and advanced stages of TNBC.

In March, the EC approved the use of Tecentriqin combination with Avastin (bevacizumab), paclitaxel and carboplatin as the first-line therapy for metastatic non-squamous non-small cell lung cancer (NSCLC).